Review



sgrna against chuk gene  (Benchling Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Benchling Inc sgrna against chuk gene
    A , B Schematic representation of the strategy used for the vivo intrasplenic metastasis assay with PDO5 in nude mice and photograph of the liver metastases ( A ); and bar chart with the quantification of the number of macroscopic metastases in the different experimental conditions WT, IKKα KO and WT followed by vemurafenib treatment ( B ) (n = 8 (WT), 7 (KO) and 8 (WT+Vemur.) mice examined). C Representative microscopic images of the immunohistochemistry analysis of the activated fibroblast marker SMA and the proliferation marker KI67 in the livers of mice transplanted with PDO5 of the indicated genotypes, and quantification of the data ( n = 6 (WT) and 8 (KO) tumor samples examined). D , E Kaplan-Meier curves of disease-free (DFS) and overall survival (OS) over time for CRC patients included in the metacohort according to <t>CHUK</t> levels using the optimal values as cutoff for patient stratification. Patients at stages II + III ( D ) or all stages ( E ) were included in the analysis. Kaplan-Meier curve estimates are shown with a 95% confidence interval. Statistical tests; B Data are presented as mean ± SD, ordinary one-way ANOVA and Tukey’s multiple comparisons test (n.s. p -value = 0.7671); C Data are presented as box plots showing the median, the 25th–75th percentiles, and the minimum and maximum values, unpaired two-tailed t test (n.s. p -value > 0.05). Source data are provided as a Source Data file.
    Sgrna Against Chuk Gene, supplied by Benchling Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sgrna+against+chuk+gene/pmc12881549-270-1-8?v=Benchling+Inc
    Average 86 stars, based on 1 article reviews
    sgrna against chuk gene - by Bioz Stars, 2026-07
    86/100 stars

    Images

    1) Product Images from "Tight junction-high and CDH17-positive cell population is the source of colorectal cancer liver metastases"

    Article Title: Tight junction-high and CDH17-positive cell population is the source of colorectal cancer liver metastases

    Journal: Nature Communications

    doi: 10.1038/s41467-025-68169-3

    A , B Schematic representation of the strategy used for the vivo intrasplenic metastasis assay with PDO5 in nude mice and photograph of the liver metastases ( A ); and bar chart with the quantification of the number of macroscopic metastases in the different experimental conditions WT, IKKα KO and WT followed by vemurafenib treatment ( B ) (n = 8 (WT), 7 (KO) and 8 (WT+Vemur.) mice examined). C Representative microscopic images of the immunohistochemistry analysis of the activated fibroblast marker SMA and the proliferation marker KI67 in the livers of mice transplanted with PDO5 of the indicated genotypes, and quantification of the data ( n = 6 (WT) and 8 (KO) tumor samples examined). D , E Kaplan-Meier curves of disease-free (DFS) and overall survival (OS) over time for CRC patients included in the metacohort according to CHUK levels using the optimal values as cutoff for patient stratification. Patients at stages II + III ( D ) or all stages ( E ) were included in the analysis. Kaplan-Meier curve estimates are shown with a 95% confidence interval. Statistical tests; B Data are presented as mean ± SD, ordinary one-way ANOVA and Tukey’s multiple comparisons test (n.s. p -value = 0.7671); C Data are presented as box plots showing the median, the 25th–75th percentiles, and the minimum and maximum values, unpaired two-tailed t test (n.s. p -value > 0.05). Source data are provided as a Source Data file.
    Figure Legend Snippet: A , B Schematic representation of the strategy used for the vivo intrasplenic metastasis assay with PDO5 in nude mice and photograph of the liver metastases ( A ); and bar chart with the quantification of the number of macroscopic metastases in the different experimental conditions WT, IKKα KO and WT followed by vemurafenib treatment ( B ) (n = 8 (WT), 7 (KO) and 8 (WT+Vemur.) mice examined). C Representative microscopic images of the immunohistochemistry analysis of the activated fibroblast marker SMA and the proliferation marker KI67 in the livers of mice transplanted with PDO5 of the indicated genotypes, and quantification of the data ( n = 6 (WT) and 8 (KO) tumor samples examined). D , E Kaplan-Meier curves of disease-free (DFS) and overall survival (OS) over time for CRC patients included in the metacohort according to CHUK levels using the optimal values as cutoff for patient stratification. Patients at stages II + III ( D ) or all stages ( E ) were included in the analysis. Kaplan-Meier curve estimates are shown with a 95% confidence interval. Statistical tests; B Data are presented as mean ± SD, ordinary one-way ANOVA and Tukey’s multiple comparisons test (n.s. p -value = 0.7671); C Data are presented as box plots showing the median, the 25th–75th percentiles, and the minimum and maximum values, unpaired two-tailed t test (n.s. p -value > 0.05). Source data are provided as a Source Data file.

    Techniques Used: Immunohistochemistry, Marker, Clinical Proteomics, Two Tailed Test



    Similar Products

    sgrna against chuk gene  (Benchling Inc)
    86
    Benchling Inc sgrna against chuk gene
    A , B Schematic representation of the strategy used for the vivo intrasplenic metastasis assay with PDO5 in nude mice and photograph of the liver metastases ( A ); and bar chart with the quantification of the number of macroscopic metastases in the different experimental conditions WT, IKKα KO and WT followed by vemurafenib treatment ( B ) (n = 8 (WT), 7 (KO) and 8 (WT+Vemur.) mice examined). C Representative microscopic images of the immunohistochemistry analysis of the activated fibroblast marker SMA and the proliferation marker KI67 in the livers of mice transplanted with PDO5 of the indicated genotypes, and quantification of the data ( n = 6 (WT) and 8 (KO) tumor samples examined). D , E Kaplan-Meier curves of disease-free (DFS) and overall survival (OS) over time for CRC patients included in the metacohort according to <t>CHUK</t> levels using the optimal values as cutoff for patient stratification. Patients at stages II + III ( D ) or all stages ( E ) were included in the analysis. Kaplan-Meier curve estimates are shown with a 95% confidence interval. Statistical tests; B Data are presented as mean ± SD, ordinary one-way ANOVA and Tukey’s multiple comparisons test (n.s. p -value = 0.7671); C Data are presented as box plots showing the median, the 25th–75th percentiles, and the minimum and maximum values, unpaired two-tailed t test (n.s. p -value > 0.05). Source data are provided as a Source Data file.
    Sgrna Against Chuk Gene, supplied by Benchling Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sgrna+against+chuk+gene/pmc12881549-270-1-8?v=Benchling+Inc
    Average 86 stars, based on 1 article reviews
    sgrna against chuk gene - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    A , B Schematic representation of the strategy used for the vivo intrasplenic metastasis assay with PDO5 in nude mice and photograph of the liver metastases ( A ); and bar chart with the quantification of the number of macroscopic metastases in the different experimental conditions WT, IKKα KO and WT followed by vemurafenib treatment ( B ) (n = 8 (WT), 7 (KO) and 8 (WT+Vemur.) mice examined). C Representative microscopic images of the immunohistochemistry analysis of the activated fibroblast marker SMA and the proliferation marker KI67 in the livers of mice transplanted with PDO5 of the indicated genotypes, and quantification of the data ( n = 6 (WT) and 8 (KO) tumor samples examined). D , E Kaplan-Meier curves of disease-free (DFS) and overall survival (OS) over time for CRC patients included in the metacohort according to CHUK levels using the optimal values as cutoff for patient stratification. Patients at stages II + III ( D ) or all stages ( E ) were included in the analysis. Kaplan-Meier curve estimates are shown with a 95% confidence interval. Statistical tests; B Data are presented as mean ± SD, ordinary one-way ANOVA and Tukey’s multiple comparisons test (n.s. p -value = 0.7671); C Data are presented as box plots showing the median, the 25th–75th percentiles, and the minimum and maximum values, unpaired two-tailed t test (n.s. p -value > 0.05). Source data are provided as a Source Data file.

    Journal: Nature Communications

    Article Title: Tight junction-high and CDH17-positive cell population is the source of colorectal cancer liver metastases

    doi: 10.1038/s41467-025-68169-3

    Figure Lengend Snippet: A , B Schematic representation of the strategy used for the vivo intrasplenic metastasis assay with PDO5 in nude mice and photograph of the liver metastases ( A ); and bar chart with the quantification of the number of macroscopic metastases in the different experimental conditions WT, IKKα KO and WT followed by vemurafenib treatment ( B ) (n = 8 (WT), 7 (KO) and 8 (WT+Vemur.) mice examined). C Representative microscopic images of the immunohistochemistry analysis of the activated fibroblast marker SMA and the proliferation marker KI67 in the livers of mice transplanted with PDO5 of the indicated genotypes, and quantification of the data ( n = 6 (WT) and 8 (KO) tumor samples examined). D , E Kaplan-Meier curves of disease-free (DFS) and overall survival (OS) over time for CRC patients included in the metacohort according to CHUK levels using the optimal values as cutoff for patient stratification. Patients at stages II + III ( D ) or all stages ( E ) were included in the analysis. Kaplan-Meier curve estimates are shown with a 95% confidence interval. Statistical tests; B Data are presented as mean ± SD, ordinary one-way ANOVA and Tukey’s multiple comparisons test (n.s. p -value = 0.7671); C Data are presented as box plots showing the median, the 25th–75th percentiles, and the minimum and maximum values, unpaired two-tailed t test (n.s. p -value > 0.05). Source data are provided as a Source Data file.

    Article Snippet: The sgRNA against CHUK gene was designed using Benchling and is available at Supplementary Table .

    Techniques: Immunohistochemistry, Marker, Clinical Proteomics, Two Tailed Test